Supramolecular structure of glibenclamide and β-cyclodextrins complexes

Int J Pharm. 2017 Sep 15;530(1-2):377-386. doi: 10.1016/j.ijpharm.2017.08.002. Epub 2017 Aug 2.

Abstract

Glibenclamide is an antidiabetic drug showing low bioavailability as consequence of its low solubility. To solve this drawback, the interaction with cyclodextrins has been proposed. The formation of GB-βCDs inclusion complexes was carried out using different methods, βCD derivatives and drug-to-cyclodextrin ratios. The structures of the corresponding complexes have been studied by molecular modelling, X-ray diffraction and differential thermal analysis. The dissolution behavior of inclusion complexes has been compared to that of pure GB. Dimeric inclusion complexes were obtained with different CD disposals, head-to-head for βCD and head-to-tail for HPβCD and RMβCD. Amorphous inclusion complexes were obtained by employing methods of freeze-drying or coevaporation in ammonia-water. However, crystalline structures were formed by kneading and coevaporation in ethanol/water in the case of GB-βCD complexes. The arrangement of these structures depended on the GB:βCD ratio, yielding cage type structures for 1:3 and 1:5 ratios and channel-type structures for higher GB contents. The amount of GB released and its dissolution rate was considerably increased by the use of amorphous inclusion complexes; whereas, slower GB release rates were found from crystalline inclusion complexes formed by kneading or coevaporation in ethanol/water. In addition, it was found that the porous structure strongly conditioned the GB dissolution rate from crystalline products.

Keywords: Cage and channel structures; Controlled drug release; Cyclodextrins; Glibenclamide; Porous structure.

MeSH terms

  • Calorimetry, Differential Scanning
  • Cyclodextrins
  • Glyburide / chemistry*
  • Models, Molecular
  • Solubility
  • X-Ray Diffraction
  • beta-Cyclodextrins / chemistry*

Substances

  • Cyclodextrins
  • beta-Cyclodextrins
  • Glyburide